Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity

Human Gene Therapy

Volumn 8, Issue 2, 1997, Pages 177-185

  Xu, M ^a   Kumar, D ^a   Srinivas, S ^a   Detolla, L J ^a   Yu, S F ^a   Stass, S A ^a   Mixson, A J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL ACETYLTRANSFERASE; LIPOSOME; PROTEIN P53;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL COUNT; BREAST TUMOR; CANCER INHIBITION; CLINICAL CHEMISTRY; CONTROLLED STUDY; DNA TRANSFECTION; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0031038841     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.2-177     Document Type: Article

References (41)

1. ALLEN, T.M., and PAPAHAJOPOULOS, D. (1993). Optimal liposomal drug action: From serendipity to targeting. In Liposome Technology, vol. III. G. Gregoriadis, ed. (CRC Press, Boca Raton, FL).
2. BLAGOSKLONNY, M.V., SCHULTE, T.W., NGUYEN, P., MIMNAUGH, E.G., TREPEL, J., and NECKERS, L. (1995). Taxol induction of p21WAF1 and p53 requires c-raf. Cancer Res. 55, 4623-4626.
3. BOOKSTEIN, R., SHEW, J.Y., CHEN, P.L., SCULLY, P., and LEE, W.H. (1990). Suppression of tumorigenicity in human prostate carcinoma cells by replacing a mutated RB gene. Science 247, 712-715.
4. BUCKBINDER, L., TALBOTT, R., VELASCO-MIGUEL, S., TAKENAKA, I., FAHA, B., SEIZINGER, B.R., and KLEY, N. (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377, 646-649.
5. CANONICO, A.E., CANARY, J.T., MEYRICK, B.O., and BRIGHAM, K.L. (1994). Systemic intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits. Am. J. Respir. Cell. Mol. Biol. 10, 24-29.
6. CASEY, G., PLUMMER, S., HOELTGE, G., SCANLON, D., FASCHING, C., and STANBRIDGE, E.J. (1993). Functional evidence for a breast cancer growth suppressor gene on chromosome 17. Hum. Mol. Genet. 2, 1921-1927.
7. CHENG, J., YEE, J.-K., YEARGIN, J., FRIEDMAN, T., and HAAS, M. (1992). Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res. 52, 222-226.
8. DAMERON, K., VOPERT, O.V., TAINSKY, M.A., and BOUCK, N. (1994). Control of angiogenesis in fibroblast by p53 regulation of thrombospondin 1. Science 265, 1582-1584.
9. DEBS, R., FREEDMAN, L., EDMUNDS, S., GAENSLER, K.L., DUZGUNES, N., and YAMAMOTO, K.R. (1990). Regulation of gene expression in vivo by liposome-mediated delivery of a purified transcription factor. J. Biol. Chem. 265, 10189-10192.
10. DUFFY, M.J. (1993). Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin. Biochem. 26, 439-447.
11. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W., and VOGELSTEIN, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
12. ENOCK, T., and NORBURY, C. (1995). Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biol. Sci. 20, 426-431.
13. FELGNER, J.H., KUMAR, R., SRIDAR, C.N., WHEELER, C.J., TSAI, Y.J., BORDER, R., RAMSEY, P., MARTIN, M., and FELGNER, P.L. (1994). Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269, 2550-2561.
14. FUJIWARA, T., CAI, D.W., MUKHOPAKHYAY, T., GRIMM, E.A., and ROTH, J.A. (1994). Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86, 1458-1462.
15. HALDAR, S., NEGRINI, M., MONNE, M., SABIONI, S., and CROCE, C.M. (1994). Down-regulation of bcl-2 in p53 in breast cancer cells. Cancer Res. 54, 2095-20597.
16. HARLAN, R.E., MONDAL, D., COLEMAN, R., and PRAKASH, O. (1991). Immunocytochemical localization of chloramphenicol acetyltransferase as a single-cell marker of transfected and transgenic cells. BioTechniques 10, 304-306.
17. HARPER, J.W., ADAMI, G.R., WEI, N., KIYOMARSI, K., and ELLEDGE, S.J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
18. HOFLAND, H., and HUANG, L. (1995). Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. Biochemical Biophys. Res. Commun. 207, 492-496.
19. JAYARAMAN, L., and PRIVES, C. (1995). Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81, 1021-1029.
20. KIMURA, M., AMEMIYA, K., YAMADA, T., and SUZUKI, J. (1986). Quantitative method for measuring adjuvant-induced granuloma angiogenesis in insulin-treated diabetic mice. J. Pharmacobio-Dyn. 9, 442-446.
21. KOUZARIDES, T. (1995). Functions of pRb and p53: What's the connection? Trends Cell Biol. 5, 448-450.
22. LEE, S., ELENBAAS, B., LEVINE, A., and GRIFFITH, J. (1995). p53 and its 10 kDa C-terminal domain recognizes primary DNA damage in the form of insertion/deletion mismatches. Cell 81, 1013-1020.
23. LESOON-WOOD, L., KIM, W.H., KLEINMAN, H.K., WEEINTRAUB, B.D., and MIXSON, A.J. (1995). Systemic gene therapy with p53 reduces growth of a malignant human breast cancer in nude mice. Hum. Gene Ther. 6, 395-405.
24. LEVINE, A.J. (1989). The p53 tumor suppressor gene and gene product. Princess Takamatsu Symp. 20, 221-230.
25. MARSHALL, J. (1995). The trouble with vectors. Science 269, 1051-1055.
26. MIYASHITA, T., and REED, J.C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
27. NABEL, E.G., PLAUTZ, G., and NABEL, G.J. (1990). Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249, 1285.
28. NABEL, E.G., GORDON, D., YANG, Z.-H., XU, L., SAN, H., PLAUTZ, G.E., WU, B.-Y., HUANG, L., and NABEL, G.J. (1992). Gene transfer in vivo with DNA-liposome complexes: Lack of autoimmunity and gonadal localization. Hum. Gene Ther. 3, 649-656.
29. ONO, T., FUJINO, Y., TSUCHIYA, T., and TSUDA, M. (1990). Stimulation of biosynthesis of nerve growth factor by acidic fibroblast growth factor in cultured mouse astrocytes. Neurosci. Lett. 117, 259-263.
30. PORTER-JORDAN, K., and LIPPMAN, M.E. (1994). Overview of the biologic markers of breast cancer. Hematol. Oncol. Clin. North Am. 8, 73-100.
31. ROEMER, K., and FRIEDMANN, T. (1994). Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Ann. NY Acad. Sci. 716, 265-280.
32. ROTH, J.A., NGUYEN, D., LAWRENCE, D.D., KEMP, B.I., CARRASCO, C.H., PERSON, D.Z., HONG, W.K., KOMAKI, R., LEE, J.J., NESBITT, J.C., PISTERS, K.M.W., PUTNAM, J.B., SCHEA, R., SHIN, D.M., WALSH, G.L., DOLORMENTE, M.M., HAN, C-I., MARTIN, F.D., YEN, N., XU, K., STEPHENS, L.C., MCDONNELL, T.J., MUKHOPADHYAY, T., and CAI, D. (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985-991.
33. SAWAN, A., RANDALL, B., ANGUS, B., WRIGHT, C., HENRY, J.A., OSTROWSKI, J., HENNESSEY, C., LENNERD, T.W., CORBETT, I., and HÖRNE, C.H. (1992). Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study. J. Pathol. 168, 23-28.
34. SIDKY, Y.A., and AUERBACH, R. (1975). Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs-host reaction. J. Experiment. Med. 141, 1084-1100.
35. STEWART, M.J., PLAUTZ, G.E., BUONO, L.D., YANG, Z.Y., XU, L., GAO, X., HUANG, L., NABEL, E.G., and NABEL, G.J. (1992). Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum. Gene Ther. 3, 267-275.
36. TILKINS, M.L., HAWLEY-NELSON, P., and BATTISTA, P.J. (1994). Transient transfection of endothelial cells. Focus 16, 117-119.
37. VAN MEIR, E.G., POVERINI, P.J., CHAZIN, V.R., HUANG, H.-J.S., DE TRIBOLET, N., and CAVENEE, W.K. (1994). Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet. 8, 171-176.
38. VISSCHER, D.W., SARKER, F.H., and CRISSMAN, J.D. (1992). Clinical significance of pathologic, cytometric, and molecular parameters in carcinoma of the breast. Adv. Pathol. Lab. Med. 5, 123-161.
39. XIONG, Y., HANNON, G.J., ZHANG, H., CASSO, D., KOBAYASHI, R., and BEACH, D. (1993). p21 is a universal inhibitor of cyclin knases. Nature 366, 701-704.
40. YONISH-ROUACH, E., RESNITZKY, D., LOTEM, J., SACHS, L., KIMCH, A., and OREN, M. (1991). Wild-type p53 induces apoptosis in myeloid leukemic cells that is inhibited by interleukin-6. Nature 352, 345-347.
41. ZHU, N., LIGGIT, D., LIU, Y., and DEBS, R. (1993). Systemic gene expression after intravenous DNA delivery into adult mice. Science 261, 209-211.